Use and cost comparison of clobazam to other antiepileptic drugs for treatment of Lennox-Gastaut syndrome

• Egile Nagusiak: Clément François (Egilea), John M. Stern (Egilea), Augustina Ogbonnaya (Egilea), Tasneem Lokhandwala (Egilea), Pamela Landsman-Blumberg (Egilea), Amy Duhig (Egilea), Vivienne Shen (Egilea), Robin Tan (Egilea)
• Formatua: Liburua
• Argitaratua: Taylor & Francis Group, 2017-01-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Background: Lennox-Gastaut syndrome (LGS) is a severe form of childhood-onset epilepsy associated with serious injuries due to frequent and severe seizures. Of the antiepileptic drugs (AEDs) approved for LGS, clobazam is a more recent market entrant, having been approved in October 2011. Recent AED...